Chemomab Therapeutics (NASDAQ:CMMB) Stock Price Up 1.9% – Time to Buy?

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) rose 1.9% during trading on Friday . The stock traded as high as $1.62 and last traded at $1.59. 34,203 shares were traded during trading, a decline of 25% from the average session volume of 45,326 shares. The stock had previously closed at $1.56.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Chemomab Therapeutics in a research note on Friday, May 8th. One analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $25.00.

Chemomab Therapeutics Price Performance

The business has a 50-day simple moving average of $1.70 and a 200 day simple moving average of $1.74. The firm has a market cap of $11.45 million, a PE ratio of -0.72 and a beta of 0.62.

Chemomab Therapeutics (NASDAQ:CMMB) last posted its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). On average, equities analysts forecast that Chemomab Therapeutics Ltd. Sponsored ADR will post -0.4 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Chemomab Therapeutics

A number of hedge funds have recently modified their holdings of the company. ADAR1 Capital Management LLC purchased a new stake in shares of Chemomab Therapeutics in the fourth quarter worth $132,000. Kestra Private Wealth Services LLC purchased a new position in shares of Chemomab Therapeutics during the 4th quarter valued at $85,000. Finally, XTX Topco Ltd purchased a new position in shares of Chemomab Therapeutics during the 4th quarter valued at $31,000. 46.05% of the stock is currently owned by institutional investors.

About Chemomab Therapeutics

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.